Hopes for Mounjaro in the obesity space
The recent European Commission’s (EC) approval of Eli Lilly’s (NYSE: LLY) Mounjaro (tirzepatide) for treating type 2 diabetes (T2D) is of paramount interest, and not only for T2D patients, as it could address vital unmet needs for other GIP/GLP-1 receptor agonist–treat Published diseases, including obesity.
The drug has the potential to address a key unmet need by introducing a new mechanism of action into the T2D space - which is expected to reach $91.6 billion by 2029 as projected by data and analytics company GlobalData in 2021 - and potentially the obesity space.
Mounjaro is a glucagon like peptide 1 (GLP-1) receptor agonist, similar to many other treatments for T2D and obesity on the market, including Novo Nordisk’s (NOV: N) Wegovy (semaglutide), the first GLP-1 agonist approved for weight loss, and the firm’s Saxenda (liraglutide).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze